{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:04:09Z","timestamp":1783609449470,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011918","name":"Hemophilia of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012423","name":"Children's Healthcare of Atlanta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000019","name":"National Hemophilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R15HL135658"],"award-info":[{"award-number":["R15HL135658"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL137128"],"award-info":[{"award-number":["HL137128"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U54HL141981"],"award-info":[{"award-number":["U54HL141981"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006778","name":"Georgia Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jtha.2023.11.010","type":"journal-article","created":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T01:29:06Z","timestamp":1700962146000},"page":"633-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction"],"prefix":"10.1016","volume":"22","author":[{"given":"Christopher W.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan N.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna M.","family":"Branella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Childers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Clint","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Trent","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Doering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.11.010_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.11.010_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.11.010_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.11.010_bib4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.11.010_bib5","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(22)00178-8","article-title":"Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success","volume":"9","author":"George","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.11.010_bib6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.ymthe.2022.06.002","article-title":"Worldwide use of factor IX Padua for hemophilia B gene therapy","volume":"30","author":"Samelson-Jones","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.11.010_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/d41586-022-04327-7","article-title":"Researchers welcome $3.5-million haemophilia gene therapy - but questions remain","volume":"612","author":"Naddaf","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.11.010_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.11.010_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240896","article-title":"Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa","volume":"15","author":"Nichols","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.11.010_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1160\/TH09-11-0792","article-title":"FIX-triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis","volume":"104","author":"Kao","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib11","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1074\/jbc.273.20.12089","article-title":"Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity","volume":"273","author":"Chang","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.11.010_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nbt.3762","article-title":"Mining ancient proteins for next-generation drugs","volume":"35","author":"Lazarus","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.11.010_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"Zakas","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.11.010_bib14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/bloodadvances.2020002971","article-title":"Molecular coevolution of coagulation factor VIII and von Willebrand factor","volume":"5","author":"Zakas","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.11.010_bib15","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/bloodadvances.2021004742","article-title":"Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction","volume":"5","author":"Knight","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.11.010_bib16","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41929-022-00856-6","article-title":"Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme","volume":"5","author":"Blazeck","year":"2022","journal-title":"Nat Catal"},{"key":"10.1016\/j.jtha.2023.11.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102154","article-title":"Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome","volume":"24","author":"Hendrikse","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jtha.2023.11.010_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nbt.4172","article-title":"Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction","volume":"36","author":"Koblan","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.11.010_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41564-022-01265-y","article-title":"Evolution of CRISPR-associated endonucleases as inferred from resurrected proteins","volume":"8","author":"Alonso-Lerma","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jtha.2023.11.010_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-cell-directed bioengineering approaches for gene therapy of hemophilia A","volume":"9","author":"Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.11.010_bib21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/hum.2020.099","article-title":"Development of a clinical candidate AAV3 vector for gene therapy of hemophilia B","volume":"31","author":"Brown","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.11.010_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nprot.2007.132","article-title":"Gene splicing and mutagenesis by PCR-driven overlap extension","volume":"2","author":"Heckman","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jtha.2023.11.010_bib23","first-page":"51","article-title":"A\u00a0Highly productive CHO cell line secreting human blood clotting factor IX","volume":"10","author":"Kovnir","year":"2018","journal-title":"Acta Naturae"},{"key":"10.1016\/j.jtha.2023.11.010_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2013.09.002","article-title":"Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports","volume":"938","author":"Ribeiro","year":"2013","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jtha.2023.11.010_bib25","doi-asserted-by":"crossref","first-page":"13922","DOI":"10.1074\/jbc.M513124200","article-title":"A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation","volume":"281","author":"Parker","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.11.010_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.11.010_bib27","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jth.15793","article-title":"Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition","volume":"20","author":"Childers","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib28","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood.2022015807","article-title":"Cryo-EM structure of the prothrombin-prothrombinase complex","volume":"139","author":"Ruben","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.010_bib29","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2023.11.010_bib30","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.str.2009.10.011","article-title":"Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa","volume":"17","author":"Z\u00f6gg","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.jtha.2023.11.010_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.11.010_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102721","article-title":"Gene therapy: challenges in cell culture scale-up","volume":"75","author":"Shupe","year":"2022","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jtha.2023.11.010_bib33","first-page":"36","article-title":"Top challenges facing gene therapy development","volume":"41","author":"Meagher","year":"2021","journal-title":"Genet Eng Biotechnol News"},{"key":"10.1016\/j.jtha.2023.11.010_bib34","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2020006005","article-title":"Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua","volume":"137","author":"Nair","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.010_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.omtm.2020.03.007","article-title":"Site-directed mutagenesis improves the transduction efficiency of capsid library-derived recombinant AAV vectors","volume":"17","author":"Ran","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.11.010_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2021.08.001","article-title":"Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette","volume":"23","author":"Kumar","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.11.010_bib37","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/jth.12731","article-title":"Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A","volume":"12","author":"Quade-Lyssy","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib38","article-title":"$3.5-Million hemophilia gene therapy is world\u2019s most expensive drug","author":"Naddaf","year":"2022","journal-title":"Sci Am"},{"key":"10.1016\/j.jtha.2023.11.010_bib39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.11.010_bib40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2020.00494","article-title":"The immune response to the FVIII gene therapy in preclinical models","volume":"11","author":"Patel","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.11.010_bib41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.11.010_bib42","doi-asserted-by":"crossref","first-page":"25393","DOI":"10.1074\/jbc.M105432200","article-title":"Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa","volume":"277","author":"Chang","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.11.010_bib43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.11.010_bib44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/hae.13947","article-title":"The European Association for Haemophilia and Allied Disorders (EAHAD) coagulation factor variant databases: important resources for haemostasis clinicians and researchers","volume":"26","author":"McVey","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.11.010_bib53","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1538-7836.2010.03913.x","article-title":"Generation of a novel factor IX with augmented clotting activities in vitro and in vivo","volume":"8","author":"Lin","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib45","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.11.010_bib46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1160\/TH13-02-0154","article-title":"Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-2836(82)90515-0","article-title":"A\u00a0simple method for displaying the hydropathic character of a protein","volume":"157","author":"Kyte","year":"1982","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jtha.2023.11.010_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1538-7836.2011.04605.x","article-title":"Correlation of factor IXa subsite modulations with effects on substrate discrimination","volume":"10","author":"Neuenschwander","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.010_bib49","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1093\/emboj\/16.22.6626","article-title":"Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants","volume":"16","author":"Hopfner","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.jtha.2023.11.010_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0969-2126(99)80125-7","article-title":"Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding","volume":"7","author":"Hopfner","year":"1999","journal-title":"Structure"},{"key":"10.1016\/j.jtha.2023.11.010_bib51","doi-asserted-by":"crossref","first-page":"25032","DOI":"10.1074\/jbc.M302174200","article-title":"Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa","volume":"278","author":"Yang","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.11.010_bib52","doi-asserted-by":"crossref","DOI":"10.1098\/rsbl.2019.0374","article-title":"The origin of platelets enabled the evolution of eutherian placentation","volume":"15","author":"Martin","year":"2019","journal-title":"Biol Lett"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623008486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623008486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:41:11Z","timestamp":1761536471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623008486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1538783623008486"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.11.010","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}